8-KOther Events

Edwards Lifesciences Corp 8-K Report (Jul 16, 2001)

Filed July 16, 2001For Securities:EW

Summary

This 8-K filing from Edwards Lifesciences Corporation (EW) on July 16, 2001, reports the completion of a significant asset disposition. On July 1, 2001, the company sold the stock of its subsidiary, Edwards Lifesciences Cardiovascular Resources, Inc. (ELCVR), to an affiliate of Fresenius Medical Care AG for approximately $45 million in cash. ELCVR was primarily involved in providing perfusion and related clinical services, with assets located in the United States and Puerto Rico. The filing includes unaudited pro forma financial information to illustrate the impact of this sale on the company's financial statements. This pro forma data adjusts historical results for the three months ended March 31, 2001, and the full year ended December 31, 2000, as if the disposition had occurred at the beginning of those periods. This information is crucial for investors to understand the standalone financial performance and structure of Edwards Lifesciences post-divestiture.

Key Highlights

  • 1Edwards Lifesciences completed the sale of its subsidiary, Edwards Lifesciences Cardiovascular Resources, Inc. (ELCVR), on July 1, 2001.
  • 2The sale generated approximately $45 million in cash proceeds.
  • 3ELCVR's business primarily consisted of perfusion services and related clinical services.
  • 4The filing provides unaudited pro forma financial statements reflecting the impact of the sale as if it occurred earlier.
  • 5Pro forma net sales for Q1 2001 are shown as $160.8 million, down from historical $191.9 million, indicating the revenue impact of the divestiture.
  • 6Pro forma net loss for the full year 2000 is presented as ($268.0 million), adjusted from historical ($271.5 million), with a note that historical 2000 earnings were part of Baxter International Inc.
  • 7The pro forma balance sheet at March 31, 2001, shows an increase in cash by $45 million due to the sale.

Frequently Asked Questions

Edwards Lifesciences sold the stock of its subsidiary, Edwards Lifesciences Cardiovascular Resources, Inc. (ELCVR), which was involved in providing perfusion services and related clinical services.

The company received approximately $45 million in cash proceeds from the sale.

The unaudited pro forma financial information is provided to show how the company's historical financial statements for the three months ended March 31, 2001, and the year ended December 31, 2000, would have looked if the sale of ELCVR had occurred at the beginning of those periods. This helps investors understand the ongoing business performance of Edwards Lifesciences as a standalone entity.

The sale of ELCVR reduced net sales and adjusted earnings. For instance, pro forma net sales for the first quarter of 2001 were $160.8 million compared to historical $191.9 million. The pro forma net loss for the full year 2000 was approximately $268 million, reflecting the removal of ELCVR's operations.